Latest news with #Xarelto
Yahoo
27-05-2025
- Business
- Yahoo
1 Top Dividend Stock to Buy for a Lifetime of Passive Income
Johnson & Johnson faces challenges including legal and regulatory troubles, and slow top-line growth. The healthcare leader has a solid and diversified business that can overcome these headwinds. J&J has increased its dividend for 62 consecutive years. 10 stocks we like better than Johnson & Johnson › There are hundreds of dividend stocks on the market, but they don't all offer the same level of security. Some haven't increased their payouts in years. Others may provide irregular dividend hikes, which will likely stop if the economy tanks or company-specific issues hit. Still others have cut their payouts in recent years. These aren't the kind of stocks income seekers are looking for. Instead, dividend investors want corporations that consistently raise their payouts, preferably every year, and are unlikely to stop even when they face headwinds. One company that has what it takes to do that is Johnson & Johnson (NYSE: JNJ). Here's why this longtime dividend payer is worth holding on to for good. Let's start with the bear case for Johnson & Johnson. Over the past few years, it has dealt with several issues. We'll consider three. First, it is still facing a litany of lawsuits related to talc-based products that allegedly gave consumers cancer. The company recently failed to put a lid on most of these lawsuits when a judge stopped its attempt to settle with most plaintiffs. So it looks like this headwind will continue. Second, recent regulatory changes in the U.S. could eventually hurt its revenue. The U.S. Centers for Medicare and Medicaid Services (CMS) now has the authority to negotiate the prices of some of the drugs Medicare spends the most on. The first round of negotiations features three of J&J's medicines: Blood thinner Xarelto, immunosuppressant Stelara, and blood-cancer medicine Imbruvica. All will see significant price cuts for Medicare patients. Third, the company has dealt with relatively slow revenue growth. However, despite all that, Johnson & Johnson looks like an attractive long-term option for dividend-seekers. J&J didn't get to be one of the largest healthcare companies in the world by accident. The company has constantly developed newer and better products in its pharmaceutical and medical-technology businesses. It boasts a deep lineup of medicines across several therapeutic areas, including immunology, oncology, infectious diseases, and neuroscience. It has more than 10 drugs that each generate more than $1 billion in annual sales. Its med-tech unit is also diversified across several areas. Its pipeline features several dozen programs. And the drugmaker constantly earns brand-new approvals or label expansions. In other words, it has an incredibly robust underlying business that's well equipped to handle the challenges it faces. The price cuts for Xarelto, Stelara, and Imbruvica will only take effect next year. And even then, they will have a minimal impact on the company's results because none of these drugs feature in its long-term growth plans. Sales of Stelara and Imbruvica are already declining due to competitive pressure (from generics or otherwise). And while Xarelto's revenue moved in the right direction in the first quarter, the U.S. Food and Drug Administration recently approved the first generic of this medicine. There will be more Medicare price negotiations, and nobody knows yet which drugs they will target. But in the long run, Johnson & Johnson should be able to handle this problem. It can avoid price negotiations by decreasing its exposure to therapies for which Medicare -- a program for the elderly -- spends the most. And that's just one possibility, which the company's deep pipeline and ability to generate consistent cash flow should allow it to do. J&J has been around for more than 100 years; it's had to deal with changes in regulatory regimes before. Although the company's revenue growth has been slow, its recent decision to spin off its consumer health unit to focus on its biopharma and med-tech segments was partly to address that problem. Expect stronger revenue growth as it focuses more on higher-growth opportunities within its two remaining units. Lastly, Johnson & Johnson has a higher credit rating than the U.S. government. Even the barrage of lawsuits has not changed that, which is strong evidence that it has the financial capabilities to handle these challenges. A previous judge shot down J&J's attempt to settle these lawsuits via a bankruptcy maneuver for one of its subsidiaries, partly because the company's robust financial position does not put it at risk of insolvency despite the lawsuits it faces. What about the dividend? Johnson & Johnson is a Dividend King with 62 years of consecutive payout increases under its belt. The healthcare leader should continue hiking its dividend, which now yields a market-beating 3.4% yield, for a long time. Before you buy stock in Johnson & Johnson, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Johnson & Johnson wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $639,271!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $804,688!* Now, it's worth noting Stock Advisor's total average return is 957% — a market-crushing outperformance compared to 167% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of May 19, 2025 Prosper Junior Bakiny has positions in Johnson & Johnson. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy. 1 Top Dividend Stock to Buy for a Lifetime of Passive Income was originally published by The Motley Fool Sign in to access your portfolio
The Hindu
15-05-2025
- Business
- The Hindu
U.S. FDA nod for Lupin's generic of Janssen Pharma's blood thinner tablets
Drugmaker Lupin has received U.S. Food and Drug Administration (U.S. FDA) approval for Rivaroxaban Tablets USP, 10 mg, 15 mg, and 20 mg, its generic version of Janssen Pharmaceuticals' blood thinner tablet Xarelto. The product will be manufactured at its Aurangabad facility. The approved product had an estimated annual sales of $8,052 million in the U.S., Lupin said citing IQVIA MAT March 2025 numbers. Rivaroxaban Tablets USP are indicated to reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillation and for treatment of deep vein thrombosis as well as pulmonary embolism, it said. Rivaroxaban Tablets are bioequivalent to Xarelto, which Jannsen said is a blood thinner to treat and help prevent blood clots related to certain conditions involving the heart and blood vessels.
Business Upturn
15-05-2025
- Business
- Business Upturn
Alembic Pharma gets USFDA nod for Rivaroxaban tablets across four strengths; to launch 2.5 mg in Q1 FY26
By Aditya Bhagchandani Published on May 15, 2025, 13:42 IST Alembic Pharmaceuticals Limited announced on May 15 that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Rivaroxaban Tablets USP in 2.5 mg, 10 mg, 15 mg, and 20 mg strengths. These tablets are therapeutically equivalent to Xarelto, a product marketed by Janssen Pharmaceuticals, Inc., and are used to reduce the risk of major cardiovascular and thrombotic vascular events in patients with coronary artery disease (CAD) and peripheral artery disease (PAD). The company plans to launch the 2.5 mg strength in the first quarter of FY26. According to IQVIA, the estimated market size for the 2.5 mg dosage in the U.S. is $445 million for the 12 months ending March 2025, while the market size for the 10 mg, 15 mg, and 20 mg strengths collectively stands at $8,052 million. With this approval, Alembic now holds a cumulative total of 222 ANDA approvals, which includes 198 final approvals and 24 tentative approvals from the USFDA. Alembic Pharmaceuticals, headquartered in Vadodara, India, is a vertically integrated pharmaceutical company engaged in manufacturing and marketing of generic drugs globally. The company has over 5,200 field personnel and a well-established brand presence in the Indian generics market. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Yahoo
13-05-2025
- Business
- Yahoo
Bayer Q1 Earnings Beat Estimates, Crop Science Unit Hurts Sales
Bayer AG BAYRY reported first-quarter 2025 core earnings of 66 cents per American Depositary Receipt (ADR), beating the Zacks Consensus Estimates of 63 cents. The company reported earnings of 77 cents per ADR in the year-ago quarter. Core earnings of €2.49 per share deteriorated 11.7% year over year on a reported basis,mainly due to the decline in earnings in the Crop Science division. Total sales in the reported quarter were $14.46 billion (€13.74 billion), down 0.2% on a reported basis. The reported figure marginally missed the Zacks Consensus Estimate of $14.57 billion. On a currency and portfolio-adjusted basis, sales decreased 0.1% year over year. All growth rates mentioned below are on a year-over-year basis after adjusting for currency and portfolio changes. (See the Zacks Earnings Calendar to stay ahead of market-making news.) Bayer reports under three segments, namely Crop Science, Pharmaceuticals and Consumer Health. In the reported quarter, Crop Science sales decreased 3.3% to €7.58 billion. This business mainly suffered due to lower glyphosate-based product and insecticide sales. Within this segment, the Herbicides business was up 0.7% as non-glyphosate-based product sales increased, primarily driven by higher volumes in all regions. However, sales of BAYRY's glyphosate-based products dropped significantly as volumes were shifted to later quarters in Latin America and North America. Fungicide sales were up 0.5% as volume recovery slightly outweighed a decline in prices. Corn Seed & Traits sales decreased 1.7% as growth in the Asia/Pacific and Europe/Middle East/Africa regions only partly offset lower volumes in North America and lower prices in Latin America. The Insecticides business decreased 12.3% due to lower Movento sales in the Europe/Middle East/Africa region following the expiration of its registration in the EU. Sales at Cotton Seed were down 19.9% due to regulatory impacts in the United States. The Vegetable Seeds business was up 5.8% due to higher volumes and prices in Latin America. Shares of Bayer have rallied 38.1% year to date against the industry's decline of 5.9%. Image Source: Zacks Investment Research BAYRY's revenues in the Pharmaceuticals segment increased 4.1% to €4.55 billion. Nubeqa (for cancer) sales surged 77.5% to €515 million, recording gains in all regions and witnessing significant improvements in volumes, especially in the United States and the EU. Kerendia sales surged 86.6%, mainly due to a substantial rise in volumes in the United States and China. However, sales of oral anticoagulant Xarelto, co-developed with J&J JNJ, decreased 31.2% to €633 million due to competitive pressure from generics, especially in the EU and Japan. In the U.S. market, Xarelto is marketed by J&J. Bayer earns license revenues from JNJ for Xarelto sales in the United States. Sales of the ophthalmology drug, Eylea, increased 4.7% to €815 million, driven by higher volumes. The launch of Eylea 8 mg, offering longer treatment intervals, provided a boost to sales, especially in Japan and the EU. Please note that Bayer's HealthCare unit co-develops Eylea with Regeneron REGN, which records net product sales of Eylea in the United States. BAYRY records net product sales of Eylea outside the country. REGN records its share of profits/losses in connection with the sales of Eylea outside the United States. Sales of the Mirena product family (long-term contraceptive) gained 18.4%, largely driven by growth in the United States. Consumer Health sales gained 2.5% to €1.5 billion, largely driven by higher volumes in North America and Asia/Pacific. Nutritionals sales declined 5.2% while the Allergy & Cold business gained 2.1%. Dermatology sales (+2%) gained from continued strong demand for Bepanthen and Canesten. Pain & Cardio (+6.5%) and Digestive Health (+12.7%) categories boosted growth for the Consumer Health business. Bayer Aktiengesellschaft price-consensus-eps-surprise-chart | Bayer Aktiengesellschaft Quote Bayer now expects to generate sales in the range of €44.5-€46.5 billion in 2025, down slightly from the previously guided range of€45-€47 billion. The company has also lowered its EBITDA before special items guidance to €9.2-€9.7 per share in 2025, from the previously expected range of €9.3-€9.8. BAYRY currently carries a Zacks Rank #2 (Buy). Another top-ranked stock in the biotech sector is AstraZeneca AZN,also carrying a Zacks Rank #2 at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. In the past 60 days, estimates for AstraZeneca's earnings per share have increased from $4.48 to $4.50 for 2025. During the same time, earnings per share estimates for 2026 have increased from $4.95 to $4.98. Year to date, shares of AZN have gained 5.2%. AZN's earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, delivering an average surprise of 4.24%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report AstraZeneca PLC (AZN) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report Bayer Aktiengesellschaft (BAYRY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
USA Today
12-05-2025
- Health
- USA Today
Trump to sign drug price executive order. What will it say?
Trump to sign drug price executive order. What will it say? Show Caption Hide Caption Trump to sign order to cut prices of medicines Donald Trump said he would sign an order to cut prescription prices to the levels paid by other nations. An executive order to be signed by President Donald Trump on Monday, May 12, will direct his government to take actions against "discriminatory" policies in foreign countries that suppress drug prices abroad, a White House official said. The order is expected to tell the U.S. Department of Health and Human Services to adopt the policy, which would set prescription drug prices to match those of comparable countries. 'DRUG PRICES TO BE CUT BY 59%,' he said in a Truth Social post on May 12, reviving a plan from his first term. The day before, in another post, he'd said the prices would 'be REDUCED, almost immediately, by 30% to 80%.' The United States Trade Representative and the Department of Commerce will be directed to take action against "unreasonable and discriminatory policies in foreign countries that suppress drug prices abroad," a White House official said in background call with reporters. What will Trump drug price executive order say? The Secretary of Health and Human Services Robert F. Kennedy Jr. will set targets for price reductions across all markets in the U.S. within 30 days, the official said. If adequate progress is not made toward the price reduction targets, the health secretary will impose most favored nation pricing via rulemaking, according to the official. During his first term, Trump in 2020 pushed a "most favored nation" rule that would have applied to Medicare payments but was later rescinded by the Biden administration. Critics of the "most favored nation" concept argue that drug companies could game the system by securing deals with foreign governments for rebates to maintain current drug pricing in the U.S. Others say it could stifle innovation in medicine if the pharmaceutical industry loses profits. How do U.S. drug prices compare to other countries? Drug prices in the U.S. are nearly three times higher than 33 comparison countries, according to a 2024 report from the Health and Human Services department. About 67 million Americans are enrolled in Medicare. Tying Medicare drug prices to international prices is a sharply different approach than how the Biden administration attempted to lower Medicare drug prices. Under Biden's 2022 climate and health legislation, the Inflation Reduction Act, Medicare was empowered to negotiate prices with pharmaceutical companies on a limited number of medications. The Biden administration already negotiated lower prices on 10 widely prescribed drugs such as Xarelto or Eliquis, which will take effect in 2026. In January, Medicare announced another batch of 15 drugs subject to negotiation this year. Those drugs included blockbuster diabetes and weight loss drugs Ozempic and Wegovy, a cost-saving move that would take effect in 2027. Asked how Trump's plan affects Biden's Inflation Reduction Act and drug price negotiations, the White House official said that after the first round of drug price negotiations, prices still ended up "in many cases, over 200% higher than what many foreign countries get," adding that they viewed that as inadequate and that the Trump administration is taking action to go beyond what was achieved under the Inflation Reduction Act. Contributing: Joey Garrison, USA TODAY; Reuters
